Viral Vector Manufacturing Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Viral Vector Manufacturing Market Analysis

According to market research estimates, the global viral vector manufacturing market is projected to be USD 2.95 billion in 2025 and is anticipated to grow to USD 7.66 billion by 2030, achieving a compound annual growth rate (CAGR) of 21.01% throughout the forecast period from 2025 to 2030.

The market trends propelling viral vector manufacturing market growth include the rising incidence of genetic disorders, cancer, and infectious diseases, which is leading to increased demands for gene and cell therapy, the growing number of clinical studies, funding opportunities for gene therapy development, and potential uses in innovative drug delivery methods.

The high prevalence of genetic disorders, cancer, and infectious diseases is likely to boost viral vector manufacturing, thus boosting market growth. For instance, according to new estimates from the World Health Organization (WHO) in November 2024, approximately 10.3 million measles cases were reported globally in 2023, reflecting a 20% rise compared to 2022. Additionally, the statistics released by the Global Cancer Observatory in February 2024 reported that new cancer cases are anticipated to reach 21.3 million by 2025 and 24.1 million by 2030 worldwide. Thus, the increasing prevalence of infectious diseases and cancer is likely to boost the viral vector manufacturing to combat these disorders and hence propel the market growth.

Furthermore, the increasing efforts of the public and private sectors to develop viral vector vaccines have prompted market leaders and major stakeholders to invest in expanding their manufacturing capabilities. For instance, in June 2024, ProBio Inc. introduced the enhancement of its plasmid DNA and viral vector manufacturing capabilities by launching a new, state-of-the-art facility in Hopewell, New Jersey. This advanced facility will act as the central hub for North American operations, greatly improving the company’s ability to support the production of transformative cell and gene therapies across the region. Additionally, in February 2024, the New South Wales (NSW) Government revealed the development of a new company, which will be registered as Viral Vector Manufacturing Facility Pty Ltd that will manage the state-of-the-art viral vector manufacturing facility located at Westmead, aimed at producing innovative and life-saving therapies. Its construction is anticipated to be completed by the end of 2024, with Good Manufacturing Practice certification. The NSW Government allocated USD 91.5 million (AUD 134.5 million) to establish the facility and produce viral vector products for research and clinical trials. Thus, such initiatives taken by the market players and government to expand the viral vector manufacturing capabilities are likely to drive market growth.

Thus, industry analysis shows that owing to the above-mentioned factors, such as the increasing prevalence of genetic disorders, cancer, and infectious diseases and significant initiatives of government and market players, the viral vector manufacturing market has the potential to drive growth and is anticipated to expand in the future. However, the high cost of gene therapies and the challenges in scaling up viral vector manufacturing could adversely affect market development.

Viral Vector Manufacturing Market Insights and Trends

The Cancer Sub-Segment is Anticipated to Experience More Rapid Growth Within the Disease Segment

The cancer segment is expected to hold a decent share of viral vector manufacturing market growth, with a compound annual growth rate (CAGR) of 21.07%. Market analysis of the cancer segment shows that it is projected to reach USD 1.33 billion by 2024 and increase to USD 3.47 billion by 2029.

Cancer encompasses a variety of diseases marked by the uncontrolled proliferation and dissemination of abnormal cells within the body. When this growth is not regulated, it can develop tumors, harm adjacent tissues, and disrupt normal bodily functions. The increasing prevalence of cancer, rising clinical trials, and market player initiatives are likely to promote the segment growth over the forecast period. The increasing clinical trials conducted by the market players to enhance the development of gene therapies for cancer treatment are anticipated to contribute to overall viral vector manufacturing market growth. For instance, in September 2024, Vironexis Biotherapeutics obtained Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for VNX-101, a gene therapy utilizing an adeno-associated virus (AAV) vector, thereby allowing a phase 1/2 clinical trial for CD19+ acute lymphoblastic leukemia. Additionally, in June 2024, Asgard Therapeutics selected Exothera S.A., a prominent provider of nucleic acids and viral vector development and manufacturing services, to handle process development and manufacturing for its candidate AT-108 up to clinical Phases I/II. This candidate utilizes viral vector technology to reprogram cancer cells within the patient's body into conventional Type 1 Dendritic Cells (cDC1s), a rare and vital subset of immune cells essential for effective anti-tumor immunity. Thus, the rising clinical trials for developing cancer therapies are anticipated to boost the segment growth.

Additionally, market players are increasingly adopting strategies such as collaborations to sustain and/or increase their viral vector manufacturing market share, which is likely fuel the cancer segment growth. For instance, in June 2024, Charles River Laboratories International, Inc. and the Gates Institute at the University of Colorado Anschutz Medical Campus unveiled a lentiviral vector contract development and manufacturing organization (CDMO) agreement partnership. The Gates Institute planned to utilize Charles River's leading expertise in cell and gene therapy CDMO to create Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) intended for innovative chimeric antigen receptor (CAR) T-cell therapies targeting hematological cancers. Moreover, in June 2024, Charles River Laboratories International, Inc. and Captain T Cell entered into an agreement for plasmid DNA and retrovirus vector production. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will gain access to established capabilities and advisory services from a contract development and manufacturing organization (CDMO) focused on plasmid and viral vector production. This collaboration is in preparation for Captain T Cell’s upcoming Phase I clinical trial to manufacture a TCR-T cell therapy for patients with solid tumors. Thus, such collaborations among market players to utilize viral vectors in the cell and gene therapies for cancer treatment are likely to contribute to the cancer segment growth during 2024 to 2029.

The growing need for effective cancer treatments, combined with a rapid approval process and the potential of new drugs for major product innovations, are key drivers behind substantial investments in research and development of cancer therapeutics utilizing viral vectors. As a result, this positively impacts the growth of the cancer segment, which is anticipated to enhance its viral vector manufacturing market share and growth further.

By Type, Adenoviral Vector Segment is Expected to Grow Significantly with the Largest Market Share

Due to technological advancements, the adenoviral vector segment is expected to hold a significant viral vector manufacturing market share, with a projected compound annual growth rate (CAGR) of 21.34% from 2024 to 2029. It is estimated to reach a market value of around USD 0.61 billion in 2024 and grow to approximately USD 1.60 billion by 2029.

Adenoviral vectors are commonly utilized in gene therapy because they effectively transport genes to specific cells, owing to their high efficiency in transduction and ability to carry substantial genetic material. The application of adenoviral vectors in vaccine development has increased significantly due to its advantages, such as quick turnaround times for development and effectiveness in provoking strong immune responses. Thus, the characteristics and advantages of adenoviral vectors in developing therapies are likely to drive the segment growth.

The viral vector manufacturing market is segmented by type, disease, and application. By type, the market is segmented into adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, retroviral vectors, and other types. By disease, the market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. By application, the market is segmented into gene therapy and vaccinology. Other viral vectors include herpes simplex virus (HSV), vaccinia virus, and Sendai virus. Other diseases include cardiovascular, neurological, metabolic, and autoimmune disorders. The market segmentation allows stakeholders in the market, such as biotech companies and contract development and manufacturing organizations (CDMOs), to concentrate on specific requirements and adoption of viral vectors for developing therapies and modify their strategies accordingly.

North America is Anticipated to Experience Significant Growth Throughout the Forecast Period

The North American viral vector manufacturing market is forecasted to expand at a compound annual growth rate (CAGR) of 20.53% from 2024 to 2029, starting with an estimated market value of USD 0.80 billion in 2024 and rising to an anticipated USD 2.04 billion by 2029. The North America market is anticipated to secure a significant share of viral vector manufacturing during the forecast period, fuelled by factors including the increasing incidence of cancer, neurological, and genetic disorders and initiatives adopted by the key market players.

For instance, in July 2024, Genezen entered into an agreement with uniQure to acquire uniQure's commercial gene therapy operations located in Lexington, Massachusetts, for a total of USD 25 million. The Lexington facility is equipped with a commercially licensed viral vector system. It features cutting-edge laboratory space and a pilot plant, which is anticipated to become a global center of excellence for adeno-associated virus (AAV) at Genezen. This acquisition will allow Genezen to provide services from preclinical development to late-phase and commercial manufacturing. Similarly, in April 2023, Bristol Myers Squibb expanded its global cell therapy manufacturing network, allowing for in-house viral vector production at a facility in the United States. This initiative follows the company's agreement with Novartis and will enhance operations at its site in Libertyville, Illinois. The facility is equipped to produce viral vectors for both of Bristol Myers Squibb’s CAR T cell therapies, marking a significant step forward in the company’s long-term goals within cell therapy.

The continuous initiatives taken by the market players to enhance the development of cell and gene therapy products are anticipated to boost the adoption of viral vectors, hence fuelling the market growth. For instance, in June 2024, C3i Center Inc. became the first Contract Development and Manufacturing Organization (CDMO) in Canada to obtain approval for a Drug Establishment License, allowing it to produce cell therapy drug products commercially. The company is also broadening its capabilities to include the production of viral vectors, exosomes, and various autologous and allogeneic cellular therapies. Thus, the increasing development of cell and gene therapies will necessitate the use of viral vectors, hence contributing to the market growth.

In North America, factors such as market players' increasing manufacturing capabilities and facilities and the rising development of cell and gene therapies are expected to stimulate market growth of viral vector manufacturing during the forecast period. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The East Africa and Asia Pacific regions, especially countries like China, Japan, and India, are witnessing significant growth due to factors such as the growing adoption of gene and cell therapies, the rising prevalence of genetic and chronic diseases, and the effectiveness of viral vector-based vaccines.